Status:
RECRUITING
Biocollection in MyeloDysplastic Syndrome (P-MDS)
Lead Sponsor:
University Hospital, Brest
Conditions:
Myelodysplastic Syndromes
Myelodysplastic Anemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Myelodysplastic syndromes (MDS) are chronic myeloid hemopathies characterized by ineffective hematopoiesis (with peripheral cytopenias) and which contrast with a marrow of normal richness. MDS is cons...
Detailed Description
The objective of the biocollection is to respond to 3 scientific projects in MDS : Project 1: splicing anomalies in MDS with SF3B1 mutations : About 95% of the coding genes in humans are subjected to...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Major
- patient with or suspected of myelodysplastic syndrome (WHO definition) at diagnosis and/or during follow-up, which is managed at the level of the Cancer-Hematology Institute of the Brest CHRU
- Presence of biological material collected within the CRB
- Patient's consent obtained
- Exclusion Criteria :
- Minor and pregnant woman
- Lack of biological material collected within the CRB
- Refusal to participate: lack of consent - Unable to consent
- Patient under judicial protection: guardianship, curatorship ...
Exclusion
Key Trial Info
Start Date :
October 19 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 19 2032
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04869683
Start Date
October 19 2022
End Date
October 19 2032
Last Update
February 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Brest
Brest, France, 29609